{
    "ticker": "GLTO",
    "name": "Galecto, Inc.",
    "description": "Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel therapies for the treatment of fibrotic diseases and cancer. Founded in 2015, Galecto is committed to addressing significant unmet medical needs through innovative drug discovery and development. The company's lead product candidate, GB0139, is designed to target and inhibit the galectin-3 protein, which plays a pivotal role in the progression of fibrosis and cancer. By leveraging its proprietary galectin technology platform, Galecto aims to develop effective treatments that can improve patient outcomes. The company is actively engaged in clinical trials to evaluate the safety and efficacy of its therapies, with a focus on conditions such as idiopathic pulmonary fibrosis and solid tumors. With a strong pipeline and a dedicated team of scientists and professionals, Galecto is poised to make a meaningful impact in the field of biotechnology, contributing to the advancement of science and improving the lives of patients suffering from chronic diseases.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Copenhagen, Denmark",
    "founded": "2015",
    "website": "https://www.galecto.com",
    "ceo": "Hans Schambye",
    "social_media": {
        "twitter": "https://twitter.com/GalectoInc",
        "linkedin": "https://www.linkedin.com/company/galecto-inc/"
    },
    "investor_relations": "https://ir.galecto.com",
    "key_executives": [
        {
            "name": "Hans Schambye",
            "position": "CEO"
        },
        {
            "name": "Jens M. H. Burchardt",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "GB0139"
            ]
        }
    ],
    "seo": {
        "meta_title": "Galecto, Inc. | Innovative Treatments for Fibrotic Diseases and Cancer",
        "meta_description": "Galecto, Inc. is a clinical-stage biotechnology company developing novel therapies targeting fibrotic diseases and cancer. Learn more about Galecto's innovative pipeline and commitment to patient care.",
        "keywords": [
            "Galecto",
            "Biotechnology",
            "Fibrosis",
            "Cancer Treatment",
            "GB0139"
        ]
    },
    "faq": [
        {
            "question": "What is Galecto known for?",
            "answer": "Galecto is known for developing innovative therapies for fibrotic diseases and cancer, particularly its lead product candidate GB0139."
        },
        {
            "question": "Who is the CEO of Galecto?",
            "answer": "Hans Schambye is the CEO of Galecto, Inc."
        },
        {
            "question": "Where is Galecto headquartered?",
            "answer": "Galecto is headquartered in Copenhagen, Denmark."
        },
        {
            "question": "What are Galecto's main products?",
            "answer": "Galecto's main product candidate is GB0139, aimed at treating fibrotic diseases."
        },
        {
            "question": "When was Galecto founded?",
            "answer": "Galecto was founded in 2015."
        }
    ],
    "competitors": [
        "VRTX",
        "CLVS",
        "KPTI",
        "FOLD"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "JNJ"
    ]
}